Valneva SE

VALN
About the company

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.

Country: FrancePrice: $5.66Market Cap: $538.4M

Investment snapshot

0%positive consensus
Scored 1d ago

Positive

0

BUY / PASS

Neutral / negative

1 / 15

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 16 investors flag at least one profitability criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #2435 (Top 78.6%)FAILFAILFAILFAILFAILFAILFAILFAILFAILFAILFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

Annual history · FY 2025

Latest source filing: 2026-03-17

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-17

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-17

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-17

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-17

Score computed: 2026-11-14

Annual history · FY 2025 · Market data at 2026-11-01

Latest source filing: 2026-03-17

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-17

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-17

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-17

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-17

Score computed: 2026-11-14

Annual history · FY 2025 · Market data at 2026-11-01

Latest source filing: 2026-03-17

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-03-17

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-17

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-03-17

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-17

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-17

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-03-17

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Profitability0% pass✓ 2✗ 33▾

      No clean pass — all 16 investors flag at least one profitability criterion

      Positive EPS (10 years)0/8 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)0/8 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-59.1%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-47.0% (latest)
      ✗BuffettStable or rising over 10 years
      Free Cash Flow Proxy$-115.0M
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROE-108.5%
      ✗Lynch> 15%
      EBIT / Enterprise Value-15.5%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-15.5%, ROC=-52.3%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-28.88%
      ✗PiotroskiROA > 0
      ROA Change YoY-2.45% -> -28.88% (delta: -26.43%)
      ✗PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=-13.26%, ROA=-28.88%
      ✓PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY41.9% -> 38.7%
      ✗PiotroskiImproved YoY
      Pre-Tax Income / Revenue-65.3%
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity-108.5%
      ✗Dreman> 12%
      Margin of SafetyP/B=3.9x
      ✗PabraiP/B < 1.5 or P/E < 15
      Return on Equity-64.8% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency0/7 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-47.0%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity-108.5%
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend-53.4% (2023) -> -47.0% (2025)
      ✓TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendgross margin 34.4% -> 38.7%, operating margin -53.4% -> -47.0%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-25.13%; #4699/6340 (top 74.1%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets+16.93%; #2284/3702 (top 61.7%)
      ✗AsnessTop 30% of eligible cross-section
      Net income / positive book equity-108.50%; #4628/5226 (top 88.6%)
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-0.1005; #3492/5884 (top 59.3%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years0/7 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Debt & Leverage0% pass✓ 2✗ 13▾

      No clean pass — all 12 investors flag at least one debt & leverage criterion

      LT Debt vs Net Current AssetsLT Debt $189.4M vs NCA $151.8M
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest CoverageD/E: 1.69, IC: -2.0x
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity1.69
      ✗Lynch< 0.33
      Cash - Long-term Debt$-60.6M
      ✗LynchPositive preferred
      LT Debt / Total Assets Change33.30% -> 40.43%
      ✗PiotroskiDecreased YoY
      Current Assets / Current Liabilities2.38
      ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity1.69
      ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
      Debt Levels1.69
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDAIC=-2.0x, D/EBITDA=N/A
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity1.69
      ✗Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)-1.6876; #3676/4210 (top 87.3%)
      ✗AsnessTop 30% of eligible cross-section
    • Valuation0% pass✓ 1✗ 27▾

      No clean pass — all 13 investors flag at least one valuation criterion

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio3.9x
      ✗Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-15.5%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-15.5%, ROC=-52.3%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      Price / Book Value per Share3.9x
      ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
      Valuation ReasonablenessOE Yield=-23.4%
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF YieldFCF Yield=-12.5%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/B=3.9x
      ✗MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Price vs. Trailing Low105% of trailing low ($2.69)
      ✓Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-25.13%; #4699/6340 (top 74.1%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization+0.2316; #4026/6449 (top 62.4%)
      ✗AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per Share4.99x
      ✗SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change-31.5%
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+0.3811; #2978/5247 (top 56.8%)
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization-12.50%; #3323/4519 (top 73.5%)
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date+5.20%; #2146/6202 (top 34.6%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Cash Flow0% pass✓ 1✗ 11▾

      No clean pass — all 10 investors flag at least one cash flow criterion

      Free Cash Flow Proxy$-115.0M
      ✗BuffettPositive and growing
      FCF Positive and Growing$-67.3M
      ✗LynchPositive and growing
      Operating Cash Flow$-62.1M
      ✗PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=-13.26%, ROA=-28.88%
      ✓PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      P/E or FCF YieldFCF Yield=-12.5%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive1/7 years FCF positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap-13.7%
      ✗Ackman>= 4%
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency3/7 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures$-67.3M
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization-12.50%; #3323/4519 (top 73.5%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Growth0% pass✓ 2✗ 11▾

      No clean pass — all 8 investors flag at least one growth criterion

      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthInv: 5.7% vs Rev: 16.3%
      ✓LynchInventory growth < Revenue growth
      EPS Growth Direction
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency0/7 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth3.7%
      ✗Ackman>= 5%
      Positive EPS Growth Frequency
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendgross margin 34.4% -> 38.7%, operating margin -53.4% -> -47.0%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR8.6%
      ✓SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Verdicts0% pass✗ 16▾

      Split decision: 15 FAIL · 1 NEUTRAL

      Overall verdict
      ✗GrahamFAIL (2/9)✗BuffettFAIL (0/9)✗LynchFAIL (1/7)✗GreenblattRank #2435✗PiotroskiFAIL (F-Score 2)✗DremanFAIL (1/11)✗MungerFAIL (0/4)✗PabraiFAIL (0/3)✗AkreFAIL (1/6)✗MarksFAIL (0/5)✗AckmanFAIL (1/9)✗TempletonFAIL (3/8)✗SleepFAIL (2/6)✗AsnessFAIL (Rank #2306/2370 (Top 97.3%))✗NeffFAIL (1/6)✗SchlossFAIL (1/7)•OshaughnessyNEUTRAL (Not ranked)
    • Efficiency25% pass✓ 3✗ 8▾

      6 of 8 flag VALN's efficiency — Buffett, Greenblatt, Piotroski +3 more

      Current Ratio2.38
      ✓Graham>= 2.0
      ROIC (3-5 yr avg)-73.7%
      ✗Buffett> 10%
      ROIC - WACC-83.7%
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)-52.3%
      ✗Greenblatt> 25%
      Current Ratio Change YoY2.61 -> 2.38
      ✗PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY0.34x -> 0.44x
      ✓PiotroskiImproved YoY
      Current Assets / Current Liabilities2.38
      ✓Dreman> 1.5
      Return on Invested Capital-22.7%
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=-21.3%; FY2024: ROIC=2.9%; FY2025: ROIC=-22.7%
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROICN/A (non-positive net income)
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)0/5 years above 12% (latest -22.7%)
      ✗SleepROIC > 12% in a majority of years

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Pharmaceutical Products
    SIC Sector: Chemicals & Pharmaceuticals
    Size: Small Cap($538.4M)
    Revenue: $205.2M+16.3% YoY
    Net Income: $135.3M-961.8% YoY

    Financial Snapshot

    Operating Margin-47.0%
    Return on Equity-108.5%
    Debt / Equity1.69
    Current Ratio2.38
    EPS (Diluted)$-0.80
    Shares Retired−6.8% / −24.9% 2y

    Shareholder Return

    Fiscal 2025

    Issued 6.8% of shares last year, 24.9% issued over two.

    Buybacks
    —
    Dividends
    —

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    MetricFY 2025
    Sources
    • 20-F · 2026-03-17
    FY 2024
    Sources
    • 20-F · 2025-03-24
    FY 2023
    Sources
    • 20-F · 2024-03-22
    FY 2022
    Sources
    • 20-F · 2023-03-30
    FY 2021
    Sources
    • 20-F · 2022-03-24
    Market Cap$538.4Mcurrent$939.4Mest.$1.1Best.$1.9Best.$3.6Best.
    Revenue$205.2M↑16%$176.5M↑4%$170.1M↓56%$385.2M↓2%$394.2M
    Operating Income-$96.4M↓795%$13.9M↑115%-$90.9M↑25%-$120.9M↓74%-$69.5M
    Net Income-$135.3M↓962%-$12.7M↑89%-$112.3M↑27%-$152.7M↓120%-$69.5M
    EPS (Diluted)$-0.80↓860%$-0.08↑90%$-0.81↑39%$-1.32↓56%$-0.85
    Gross Margin38.7%↓8%41.9%↑22%34.4%↑237%10.2%↓78%46.0%
    Operating Margin-47.0%↓698%7.9%↑115%-53.4%↓70%-31.4%↓78%-17.6%
    ROE-108.5%↓1506%-6.8%↑91%-79.1%↓21%-65.2%↓81%-36.0%
    Total Debt$210.5M↑8%$195.0M$195.7M↑86%$105.3M↑61%$65.5M
    Shareholders' Equity$124.7M↓34%$188.6M↑33%$141.9M↓39%$234.3M↑21%$193.2M
    Current Ratio2.38↓9%2.61↑58%1.65↑8%1.53↓4%1.59
    Debt / Equity1.69↑63%1.03↓25%1.38↑207%0.45↑33%0.34
    Operating Cash Flow-$62.1M↑11%-$69.9M↑69%-$224.4M↑14%-$261.6M↓400%$87.1M
    Free Cash Flow-$67.3M↑20%-$84.4M↑65%-$240.2M↑18%-$292.7M↓1586%-$17.4M

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Pharmaceutical Products

    VALN vs Peers — Financial Grading

    Revenue$205.2MBottom 25%
    Net Income$135.3MBottom 25%
    ROE-108.5%Bottom 25%
    D/E1.69Median
    Op. Margin-47.0%Bottom 25%
    Curr. Ratio2.38Median
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    Merck & Co., Inc.MRK$364.3B$147.76$65.0B$18.3B34.7%0.94—1.542/95/94/70/3F-Score 41/11
    ABBOTT LABORATORIESABT$188.0B$108.52$44.3B$6.5B12.5%0.2518.2%1.583/94/92/71/3F-Score 53/11
    BRISTOL MYERS SQUIBB COBMY$129.7B$63.43$48.2B$7.1B38.2%2.4419.4%1.262/91/93/71/3F-Score 85/11
    BIO-TECHNE CorpTECH$11.4B$72.80$1.2B$73.4M3.8%—8.4%3.464/93/93/70/3F-Score 54/11
    REPLIGEN CORPRGEN$10.7B$167.79$738.3M$48.9M2.3%0.267.5%8.373/92/93/70/3F-Score 75/11
    IONIS PHARMACEUTICALS INCIONS$4.8B$29.06$943.7M$381.4M-78.0%3.60-40.4%3.833/91/91/70/3F-Score 43/11
    NEOGEN CORPNEOG$2.5B$11.23$870.4M$7.9M-0.4%0.76-2.5%3.823/91/92/70/3F-Score 64/11
    Pharvaris N.V.PHVS$2.4B$33.36—$206.4M-64.8%0.00——0/90/92/70/3F-Score 22/11